Abstract:BackgroundLipoprotein(a) [Lp(a)] is an LDL-like particle with apolipoprotein(a) [apo(a)] covalently attached to apolipoprotein B. Elevated Lp(a) is associated with increased risk of atherosclerotic heart disease. The structural homology of Lp(a) and plasminogen and the variable number of apo(a) kringle 4 type 2 subunits (k4t2) between individuals, up to 51 repeats and a variable MW of 300-800 kDa, presents an analytical challenge. `Selection of calibrators of specific isoform size does not fix the problem, despite manufacturer's claims to the contrary.MethodsWe have developed goat antisera to human apo(a)-specific peptides and a prototype immunoturbidimetric assay for Lp(a). We selected and synthesized 10 peptide sequences (15-30 aa each) distinct from the sequences found in k4t2 regions and plasminogen. Peptides were prepared attached to KLH (GenScript) and combined to immunize goats following a standard protocol including monthly boosters (Nittobo). Next, we assessed various sample volumes, reagent formulations and antisera dilutions to establish parameters on the Randox Imola analyzer. Cross-reactivity with recombinant k4t2 (40 mg/dL) and plasminogen (200 mg/dL, Athens Research) was assessed by comparison to the LOD (using delipidated plasma blank and low concentration samples).ResultsTiters to human Lp(a)) were positive to 1:6400 dilution of antisera, showing exceptional reactivity. Working formulation/parameters were 10 μL sample, 100 μL PBS, pH 7.4/PEG6000/detergent and 95 μL R2 (antisera). Sample/R1 was incubated for 5-minutes before addition of R2; reaction was monitored at 340 nm/37°C. LOD and linearity were also assessed. No cross-reactivity with k4t2 or plasminogen up to the concentrations tested was observed. Linearity to 330 nmol/L and LOD of 18 nmol/L were found.ConclusionsThe use of this antisera/assay eliminates the bias associated with apo(a) size polymorphisms and allows for the accurate measurement of Lp(a) particle number. More work is needed to optimize assay parameters and formulation and comprehensively validate assay performance.

Expression and characterization of human recombinant apolipoprotein(a) kringle IV-10

Probing Orientation of Immobilized Humanized Anti-Lysozyme Variable Fragment by Time-of-flight Secondary-Ion Mass Spectrometry.

Isolation and characterization of a new advanced glycation endproduct of dehydroascorbic acid and lysine

Prokaryotic Expression of Human Apolipoprotein E and Analyses of the Molecular Interaction Between ApoE and PrP Proteins in Vitro

A-215 Feasibility of a unique homogenous assay for lipoprotein(a) particle number without bias from apo(a) size isoforms

Characterization of a human apolipoprotein a-I construct expressed in a bacterial system

The structure of human apolipoprotein E2, E3 and E4 in solution 1. Tertiary and quaternary structure

A simple approach for human recombinant apolipoprotein E4 expression and purification

Cloning and expression of apolipoprotein E3 and its variant apoE2 and apoE4

Expression Of Biologically Active Kringle 5 Domain Of Human Plasminogen In Escherichia Coli

Screening, characterization and specific binding mechanism of aptamers against human plasminogen Kringle 5

Apolipoprotein Α-IV is a Novel Ligand of Platelet Αiibβ3 Integrin and an Endogenous Thrombosis Inhibitor: Measurement of Single-Molecular Interactions by Biomembrane Force Probe

Construction of prokaryotic expression vector of recombinant human apolipoprotein A5 and its analysis and identification

Abstract 53: An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma

Expression of Human Plasminogen Kringle 5 As Fusion Protein with Truncated Hifnγ Gene in Escherichia Coli

Expression,purification and Identification of Kringle Domain Deletion Mutant of Human Plasminogen in Pichia Pastoris

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux

Apolipoprotein E expression and purification

Molecular recognition and interaction between human plasminogen Kringle 5 and voltage-dependent anion channel-1 by biological specificity technologies and molecular dynamic simulation

Expression and functional reconstitution of a recombinant antibody (Fab′) specific for human apolipoprotein B-100

Site-Selective Lysine Acetylation of Human Immunoglobulin G for Immunoliposomes and Bispecific Antibody Complexes